Skip to main content
TELO
NASDAQ Life Sciences

Telomir Pharmaceuticals Secures FDA IND Clearance for Telomir-Zn in Breast Cancer

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$1.49
Mkt Cap
$49.852M
52W Low
$1.05
52W High
$3.1
52W Position info
42% above low
Off High info
52% below high
Rel. Volume info
1.9× avg
Market data snapshot near publication time

TELO sits 42% above its 52-week low of $1.05 on elevated volume (1.9× avg).

Summary

Telomir Pharmaceuticals announced FDA clearance of its Investigational New Drug (IND) application for Telomir-Zn, enabling the initiation of a Phase 1/2 clinical trial for triple-negative breast cancer.


Key Events · Product Development and Regulatory · TELO

  • FDA IND Clearance

    The U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for Telomir-Zn.

  • Target Indication

    Telomir-Zn is being developed for the treatment of patients with advanced or metastatic triple-negative breast cancer.

  • Clinical Trial Initiation

    The company plans to initiate a First-in-Human Phase 1/2 clinical trial in the first half of 2026.

  • Trial Design

    The planned study will include a dose-escalation Phase 1 for safety and preliminary activity, followed by a Phase 2 portion evaluating objective response rate (ORR) as the primary endpoint.


Analysis · TELO · Life Sciences

This FDA clearance is a critical milestone for Telomir Pharmaceuticals, allowing them to advance their lead product candidate, Telomir-Zn, into human clinical trials. For a company previously noted with a going concern warning, this progress in their drug development pipeline provides a significant positive signal, demonstrating tangible advancement towards potential future commercialization. The planned Phase 1/2 trial will assess safety, tolerability, and preliminary efficacy, with results being crucial for the company's long-term viability and investor confidence.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TELO was trading at $1.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.9M. The 52-week trading range was $1.05 to $3.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TELO - Latest Insights

TELO
Nov 06, 2026, 4:41 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.740
Real-time Price: $0.502 info
Change: -$0.238 (-32%) info
Market Cap: $36.145M info
TELO
Oct 27, 2026, 4:30 PM EDT
Filing Type: S-3
Importance Score:
7
Price at Filing: $1.02
Real-time Price: $0.502 info
Change: -$0.518 (-51%) info
Market Cap: $36.145M info
TELO
Oct 06, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.24
Real-time Price: $0.502 info
Change: -$0.738 (-60%) info
Market Cap: $36.145M info
TELO
Oct 06, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.28
Real-time Price: $0.502 info
Change: -$0.778 (-61%) info
Market Cap: $36.145M info
TELO
Aug 13, 2026, 5:10 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $1.05
Real-time Price: $0.502 info
Change: -$0.548 (-52%) info
Market Cap: $36.145M info